Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial

AIDS

Volumn 10, Issue 13, 1996, Pages 1501-1507

  Reyes Terán, Gustavo ^a   Sierra Madero, Juan G ^a   Martínez Del Cerro, Veronica ^a   Arroyo Figueroa, Hugo ^a   Pasquetti, Alberto ^a   Calva, Juan J ^a   Ruiz Palacios, Guillermo M ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

HIV; Thalidomide; Wasting syndrome

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; THALIDOMIDE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ERYTHEMA; FEMALE; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MEXICO; MONONUCLEAR CELL; MUSCLE ATROPHY; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; T LYMPHOCYTE; TREATMENT FAILURE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 0029800251     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199611000-00007     Document Type: Article

References (38)

1. Gorbach SL, Knox TA, Roubenoff R: Interactions between nutrition and infection with human immunodeficiency virus. Nutr Rev 1993, 51:226-234.
2. Centers for Disease Control: Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987, 36(suppl 1):3S-15S.
3. Kotler DP, Tierney AR, Wang J, Pierson RN: Magnitude of body cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989, 50:444-447.
4. Guenter P, Muurahainen N, Simons G, et al.: Relationship among nutritional status, disease progression and survival in HIV infection. J Acquir Immune Defic Syndr 1993, 6:1130-1138.
5. Kotler DP, Wang J, Pierson RN. Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 985, 42:1255-1265.
6. Macallan DC, Noble C, Baldwin C, Foskett M, McManus T, Griffin GE: Prospective analysis of patterns of weigh change in stage IV human immunodeficiency virus infection. Am J Clin Nutr 1993, 58:417-424.
7. Grunfeld C, Feingold KR: Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992, 327:329-337.
8. Grunfeld C: What causes wasting in AIDS? N Engl J Med 1995, 333:123-124.
9. Pantaleo G, Graziosi C, Fauci AS: The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993, 328:327-335.
10. Coodley GO, Loveless MO, Merrill TM: The HIV wasting syndrome: a review. J Acquir Immune Defic Syndr 1994, 7:681-694.
11. Macallan DC, Noble C, Baldwin C, et al.: Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995, 333:83-88.
12. Von Roenn JH, Armstrong D, Kotler DP, et al.: Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994, 121:393-399.
13. Schambelan M, Mulligan K, Grunfeld C, et al.: Recombinant human growth hormone increases lean body mass and improves functional performance in patients with HIV-associated wasting. Second National Conference on Human Retroviruses and Related Infections. Washington, DC, January 1995 [abstract LB15].
14. Dournon E, Matheron S, Rozenbaum W, et al.: Effects of zidovudine in 365 consecutive patients with AIDS or AIDS-related complex. Lancet 1988, ii:1297-1302.
15. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G: Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes. J Exp Med 1991, 173:699-703.
16. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation. J Exp Med 1993, 177:1675-1680.
17. Makonkawkeyoon S, Limson-Pobre RNR, Moreira A, Schauf V, Kaplan G: Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993, 90:5974-5978.
18. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975, 31:103-115.
19. Donner A: Approaches to sample size estimation in the design of clinical trial - a review. Statist Med 1984, 3:199-214.
20. Heymsfield SB, McManus C, Smith J, Stevens V, Nixon DW: Anthropometric measurement of muscle mass: revised equations for calculating bone-free arm muscle area. Am J Clin Nutr 1982, 36:680-690.
21. Hollinger FB (Ed): ACTG Virology Manual for HIV Laboratories. Version 2.0. January 1993: MIC 1-5.
22. Colton T. Statistics in Medicine. Boston: Little and Brown; 1974.
23. Hoover DR, Saah AJ, Bacellar H, et al.: Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993, 329:1922-1926.
24. Rabeneck L, Risser JMH, Crane MM, et al.: A comparison of anthropometry and bioelectrical impedance in the estimation of body composition in HIV-infected individuals. Nutr Res 1993, 13:275-285.
25. Risser JMH, Rabeneck L, Foote LW, Klish WJ: A comparison of fat-free mass estimates in men infected with the human immunodeficiency virus. J Parenter Enteral Nutr 1995, 19:28-32.
26. Segal KR, Van Loan M, Fitzgerald PI, Hodgdon JA, Van Itallie TB: Lean body mass estimation by bioelectric impedance analysis: a four-site cross-validation study. Am J Clin Nutr 1988, 46:537-556.
27. Von Roenn JH, Murphy RL, Weber KM, Williams LM, Weitzman SA: Megestrol acetate for treatment of cachexia associated with human immunodeficiency (HIV) infection. Ann Intern Med 1988, 109:840-841.
28. Kotler DP, Tierney AR, Culpepper-Morgan JA, Wang J, Pierson RN Jr: Effect of home total parenteral nutrition upon body composition in patients with acquired immunodeficiency syndrome. J Parenter Enteral Nutr 1990, 14:454-458
29. Kotler DP, Tierney AR, Altilio D, Wang J, Pierson RN: Body mass repletion during ganciclovir treatment of cytomegalovirus infections in patients with acquired immunodeficiency syndrome. Arch Intern Med 1989, 149:901-905.
30. Risser JMH, Rabeneck L, Foote LW: Prevalence of wasting in men infected with human immunodeficiency virus seeking routine medical care in an outpatient clinic. J Am Diet Assoc 1995, 95:1025-1026.
31. Weinroth SE, Parenti DM, Simon GL: Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches. Infect Agents Dis 1995, 4:76-94.
32. Macallan DC, McNurian MA, Milne E, Calder AG, Garlick PJ, Griffin GE: Whole body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. Am J Clin Nutr 1995, 61:818-826.
33. Munis, JR, Richman DD, Kornbluth RS: Human immunodeficiency virus-1 infection of macrophages in vitro neither induces tumor necrosis factor (TNF/cachectin) gene expression nor alters TNF/cachectin induction by LPS. J Clin Invest 1990, 85:591-596.
34. Aukrust P, Liabakk NB, Müller F, Lien E, Espevik T, Frfland SS: Serum levels of tumor necrosis factor-α (TNF-α) and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994, 169:420-424.
35. Nogueira AC, Neubert R, Helge H, Neubert D: Thalidomide and the immune system. Simultaneous up- and down-regulation of different integrin receptors on white blood cells. Life Sci 1994, 55:77-92.
36. Klatzman JD, Makonkawkeyoon S, Akaresewi P, Kasinrerk W, Nakata K, Kaplan G: Treatment with thalidomide in AIDS patients. Tenth International Conference on AIDS. Yokohama, August 1994 [abstract PB0312].
37. Tramontana JM, Utaipat U, Molloy A, et al.: Thalidomide treatment reduces tumor necrosis factor alfa production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995, 1:384-397.
38. Mellin GW, Katzenstein M: The saga of thalidomide (concluded). Neuropathy to embryopathy, with case reports of congenital anomalies. N Engl J Med 1962, 267:1238-1244.